One week after intravitreal bevacizumab injection, corneal endothelial cells showed no sign of inflammation or any other complications, according to a study published in BMC Ophthalmology.
One week after intravitreal bevacizumab injection, corneal endothelial cells showed no sign of inflammation or any other complications, according to a study published in BMC Ophthalmology.
Corneal endothelial cells make up the structure of the cornea and are located at the innermost layer. An increase in intraocular pressure (IOP) can cause corneal scarring and damage the endothelial cells, leading to significant loss of vision. If these cells are damaged, it is impossible to regenerate them.
The risks of a high IOP include the function of the endothelial pump, induced corneal edema and hypoxia, and reduced intraocular blood flow.
While some injections in the cornea can lead to increased IOP, therapeutic intravitreal bevacizumab injections increase IOP for just 30 minutes, followed by a drop to normal levels. The study analyzed the momentary changes and safety of corneal endothelial cells and corneal thickness once there is an acute increase resulting from the injection.
At Dankook University Hospital in South Korea, 42 eyes (in 42 patients) were included in the study. These eyes were treated with intravitreal bevacizumab injections to treat macula edema or macular degeneration between May 2014 and January 2015. Before each injection was completed, patients took a benchmark exam that gave baseline visual acuity and optical coherence tomography, a slit-lamp examination, and a fundus examination. In addition, IOP and endothelial cell evaluations were conducted before and after injection. Two measurements were made in the cornea to assess the density of endothelial cells (CD) and the central corneal thickness (CTT). The mean IOP was calculated by taking 3 measurements from the eye.
The results showed that there was a significant increase in IOP from baseline in all patients. Before the injection, mean IOP was 11.48 and significantly increased from 49.71 mmHg at 2 minutes to 37.64 mmHg 5 minutes after the injection. After 30 minutes, IOP returned to a normal range. After 1 week, there was no sign of inflammation in any of the 42 study participants.
There was no significant correlation in changes of CTT and CD to an increase in IOP pressure. The researchers believe that further analysis of a larger sample population is needed to measure the changing patterns of corneal endothelial cells during and after intravitreal bevacizumab injection.
“When bevacizumab is intravitreally injected, an acute increase of IOP occurs, but after 30 [minutes], the IOP normalized,” the authors wrote. “During this process, endothelial cells may receive momentary compression and stretch pressure, but it is tolerable and has no harmful effects on the corneal endothelium.”
Reference
Park J, Lee M. Short-term effects and safety of an acute increase of intraocular pressure after intravitreal bevacizumab injection on corneal endothelial cells. BMC Ophthalmol. 2018;18(1):17. doi: 10.1186/s12886-018-0682-9.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.